| NCT ID | NCT06937827 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hackensack Meridian Health |
| Condition | Heart Failure With Preserved Ejection Fraction |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-06-26 |
| Primary Completion | 2027-04-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2025-06-26 with a primary completion date of 2027-04-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The transition period from hospital to home is a time of heightened risk for patients to experience adverse events, medication errors, and readmission to the hospital. Patients at the highest risk include older adults and patients with low health literacy, socioeconomic disadvantages, and/or multiple comorbidities. This project proposes to expand the existing Transitions of Care Clinic (TOCC) which was recently introduced in our institution in 2024, to bridge the gap in care between hospital discharge to home and connect discharged patients to their outpatient providers with a focus on patients with heart failure (HF). The existing TOCC, a multidisciplinary team composed of a pharmacist and a nurse practitioner, seeks to improve the services that are currently being provided to patients and enhance the transitions of care process by providing patients with education, tools, and resources to help manage their chronic disease. With this study, we propose to expand TOCC by offering extensive education to patients via iPad videos and providing them with HF tool kits prior to their discharge. We will also assist with scheduling follow appointments with their outpatient providers and follow up with patients after the appointment takes place to re-evaluate their needs and reinforce self management of heart failure. By targeting patients being treated for acute exacerbation of heart failure with preserved ejection fraction (HFpEF), this study aims to facilitate the transition of care, reduce hospital readmissions and improve patients' quality of life and satisfaction. Patients with HFpEF represent a majority of the HF patients that are readmitted at OUMC. HFpEF patients have fewer guideline recommended treatments and represent a vulnerable patient population. The HF tool kits will provide these patients with the essential tools, resources, and log sheets for self-management such as monitoring daily weights, monitoring blood pressure and heart rate. Patients provided with a kit will receive an initial phone call from TOCC within 1 to 3 days of discharge and a second phone call within 21-24-days post discharge.
Eligibility Criteria
Inclusion Criteria: * Adults ages 18 to 90 years old discharged from Ocean University Medical Center (OUMC) * Inpatient admission for heart failure with preserved ejection fraction (HFpEF) exacerbation * Patient discharged home with or without homecare Exclusion Criteria: * Refuse to participate in TOCC phone calls * Discharged to a facility * Discharged with homecare services * Discharged on hospice services * Hemodialysis * Leave against medical advice (AMA) * Pregnant * Diagnosed with dementia * Without medical capacity or unable to provide own consent
Contact & Investigator
Alexandria Berns, PharmD
PRINCIPAL INVESTIGATOR
Hackensack Meridian Health
Frequently Asked Questions
Who can join the NCT06937827 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Heart Failure With Preserved Ejection Fraction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06937827 currently recruiting?
Yes, NCT06937827 is actively recruiting participants. Contact the research team at Alexandria.Berns@hmhn.org for enrollment information.
Where is the NCT06937827 trial being conducted?
This trial is being conducted at Brick, United States.
Who is sponsoring the NCT06937827 clinical trial?
NCT06937827 is sponsored by Hackensack Meridian Health. The principal investigator is Alexandria Berns, PharmD at Hackensack Meridian Health. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.